tbuckley/cabot-search huggingface dataset:
Advancing the Sustainable Development Goals through improving eye health: a scoping review
Authors: Justine H Zhang, Jacqueline Ramke, Catherine Jan, Covadonga Bascaran, Nyawira Mwangi, João M Furtado, Sumrana Yasmin, Cynthia Ogundo, Miho Yoshizaki, Ana Patricia Marques, John Buchan, Peter Holland, Brandon A M Ah Tong, Jennifer R Evans, Nathan Congdon, Aubrey Webson, Matthew J Burton
Journal: The Lancet Planetary Health (2022)

UN member states have committed to achieving the Sustainable Development Goals (SDGs) by 2030. This Review examines the published evidence on how improving eye health can contribute to advancing the SDGs (beyond SDG 3). We identified 29 studies that showed direct benefits from providing eye health services on SDGs related to one or more of poverty (SDGs 1, 2, and 8), education (SDG 4), equality (SDGs 5 and 10), and sustainable cities (SDG 11). The eye health services included cataract surgery, free cataract screening, provision of spectacles, trichiasis surgery, rehabilitation services, and rural community eye health volunteers. These findings provide a comprehensive perspective on the direct links between eye health services and advancing the SDGs. In addition, eye health services likely have indirect effects on multiple SDGs, mediated through one of the direct effects. Finally, there are additional plausible links to other SDGs, for which evidence has not yet been established.
Mickey Mouse Sign on Bone Scan
Authors: Fiza M. Khan, Bo Chen, Amol M. Takalkar
Journal: Clinical Nuclear Medicine (2022)

Abstract An 81-year-old man with prostate adenocarcinoma demonstrated interval progression of the osteoblastic metastatic disease on surveillant bone scan with a new lumbar lesion resembling the configuration of Mickey's head (Mickey Mouse sign), a sign considered to be specific for Paget disease, even in the presence of malignancy. However, our case demonstrates that this appearance can be caused by other etiologies. In the era of SPECT/CT and MRI, it is prudent to obtain further cross-sectional correlation at the time of radionuclide bone scintigraphy to clarify the underlying cause for “Mickey Mouse sign” to prevent misinterpretation, allowing for efficient and accurate patientcare.
Abstract P2-11-16: Rate of breast biopsy referrals in <i>BRCA</i> mutation carriers: A retrospective comparative study and matched analysis
Authors: Adi Pomerantz, Daliah Tsoref, Ahuva Grubstein, Sonya Wadhawker, Yael Rapson, Itay Gadiel, Hadar Goldvaser, Ariel Hammerman, Tzipora Shochat, Eran Sharon, Rinat Yerushalmi
Journal: Cancer Research (2022)

Abstract Purpose: To evaluate the total biopsy and positive biopsy rates in women at high risk of breast cancer compared to the general population. Methods: The study group consisted of 330 BRCA mutation carriers attending the dedicated multidisciplinary breast cancer clinic of a tertiary medical center in Israel. Clinical, genetic, and biopsy data were retrieved from the central healthcare database and the medical files. Patients who were at age 50 years or older during follow-up were matched 1:10 to women in the general population referred for routine breast cancer screening at the same age, as recommended in the international guidelines. The groups were compared for rate of biopsy studies performed and percentage of positive biopsy results. Matched analysis was performed to correct for confounders. Results: The matched analysis revealed that the total biopsy rate per 1000 follow-up-years was 61.7 in the study group and 22.7 in the control group (p &amp;lt;0.001). The positive biopsy rates per 1000 follow-up-years were 26.4 and 2.0, correspondingly (p &amp;lt;0.001), and the positive biopsy percentages were 42.9% and 8.7% correspondingly (p &amp;lt;0.0001).Conclusions: BRCA mutation carriers who attend a dedicated clinic, have a 2.7 times higher biopsy rate per 1000 follow-up-years, a 13.2 times higher positive biopsy rate per 1000 follow-up-years, and a 4.9 times higher positive biopsy percentage compared with women in the general population. Keywords: Biopsy, BRCA, breast cancer, screening, high risk Citation Format: Adi Pomerantz, Daliah Tsoref, Ahuva Grubstein, Sonya Wadhawker, Yael Rapson, Itay Gadiel, Hadar Goldvaser, Ariel Hammerman, Tzipora Shochat, Eran Sharon, Rinat Yerushalmi. Rate of breast biopsy referrals in BRCA mutation carriers: A retrospective comparative study and matched analysis [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-11-16.
AN UNUSUAL CASE OF HYDRALAZINE INDUCED ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES VASCULITIS CAUSING AUTOIMMUNE MYOCARDITIS
Authors: Parth Savsani, Elie Kozaily, Reid Wilson, Mark Kauth, Matthew Dollins, Damien Patel, Upasana Jarori
Journal: Journal of the American College of Cardiology (2022)
INVASIVE HEMODYNAMIC EVALUATION OF LEFT VENTRICULAR ASSIST DEVICE OUTFLOW GRAFT STENOSIS FOLLOWED BY PERCUTANEOUS INTERVENTION
Authors: Tarun Dalia, Amandeep Goyal, Prakash Acharya, Harsh Mehta, Ioannis Mastoris, Eric Hockstad, Nicholas A. Haglund, Travis Abicht, Zubair Shah, Bhanu P. Gupta
Journal: Journal of the American College of Cardiology (2022)
Blood-based epigenome-wide analyses of cognitive abilities
Authors: Daniel L. McCartney, Robert F. Hillary, Eleanor L. S. Conole, Daniel Trejo Banos, Danni A. Gadd, Rosie M. Walker, Cliff Nangle, Robin Flaig, Archie Campbell, Alison D. Murray, Susana Muñoz Maniega, María del C. Valdés-Hernández, Mathew A. Harris, Mark E. Bastin, Joanna M. Wardlaw, Sarah E. Harris, David J. Porteous, Elliot M. Tucker-Drob, Andrew M. McIntosh, Kathryn L. Evans, Ian J. Deary, Simon R. Cox, Matthew R. Robinson, Riccardo E. Marioni
Journal: Genome biology (2022)

Abstract Background Blood-based markers of cognitive functioning might provide an accessible way to track neurodegeneration years prior to clinical manifestation of cognitive impairment and dementia. Results Using blood-based epigenome-wide analyses of general cognitive function, we show that individual differences in DNA methylation (DNAm) explain 35.0% of the variance in general cognitive function ( g ). A DNAm predictor explains ~4% of the variance, independently of a polygenic score, in two external cohorts. It also associates with circulating levels of neurology- and inflammation-related proteins, global brain imaging metrics, and regional cortical volumes. Conclusions As sample sizes increase, the ability to assess cognitive function from DNAm data may be informative in settings where cognitive testing is unreliable or unavailable.
Objective Structured Clinical Examination (OSCE), unsatisfactory results: Sequelae of the COVID-19 pandemic – Correspondence
Authors: Luisa Fernanda Hurtado Quiros, Laura Cristina Carreño Mancilla, Lesmer Alirio Galindo Ruiz, Gonzalo Andrés Domínguez-Alvarado
Journal: International Journal of Surgery (2022)
DOES TAFAMIDIS BENEFIT OCTOGENARIANS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY? ANALYSIS OF THE CLEVELAND CLINIC AMYLOID REGISTRY
Authors: Abdullah Sarkar, Diana Miranda, Jose Sleiman, Hong Liang, Lauren Ives, Craig R. Asher, Mazen A. Hanna, David G. Wolinsky
Journal: Journal of the American College of Cardiology (2022)
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Authors: Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia
Journal: Journal of Hematology & Oncology (2022)

Abstract Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies.
30-DAY READMISSION RATE FOR SYSTOLIC HEART FAILURE IN PATIENT WITH TYPE 2 DIABETES AND ITS ECONOMIC BURDEN ON HEALTHCARE
Authors: Michael A. Fatuyi, Leanne Pereira, Awfa Zain Elabidin, Vahid Namdarizandi, Vivek Sharma, Leonid Khokhlov, Mubarak H. Yusuf, Oghenesuvwe Eboh, Asimul H. Ansari, Kamal Shemisa
Journal: Journal of the American College of Cardiology (2022)
Covid-19: Oxygen shortages two years into pandemic highlight pre-covid failures, says WHO
Authors: Elisabeth Mahase
Journal: BMJ (2022)

Covid-19: Oxygen shortages two years into pandemic highlight pre-covid failures, says WHO Elisabeth MahaseTwo years into the covid-19 pandemic, access to oxygen is still a major problem in low and middle income countries, health leaders have warned.The shortages have highlighted the "abject failure" of the global community to develop and build up primary healthcare and universal health coverage over the past 20 years, said Michael Ryan, the World Health Organization's health emergencies programme executive director.
Chromosome-scale and haplotype-resolved genome assembly of a tetraploid potato cultivar
Authors: Hequan Sun, Wen-Biao Jiao, Kristin Krause, José A. Campoy, Manish Goel, Kat Folz-Donahue, Christian Kukat, Bruno Huettel, Korbinian Schneeberger
Journal: Nature Genetics (2022)

Abstract Potato is the most widely produced tuber crop worldwide. However, reconstructing the four haplotypes of its autotetraploid genome remained an unsolved challenge. Here, we report the 3.1 Gb haplotype-resolved (at 99.6% precision), chromosome-scale assembly of the potato cultivar ‘Otava’ based on high-quality long reads, single-cell sequencing of 717 pollen genomes and Hi-C data. Unexpectedly, ~50% of the genome was identical-by-descent due to recent inbreeding, which was contrasted by highly abundant structural rearrangements involving ~20% of the genome. Among 38,214 genes, only 54% were present in all four haplotypes with an average of 3.2 copies per gene. Taking the leaf transcriptome as an example, 11% of the genes were differently expressed in at least one haplotype, where 25% of them were likely regulated through allele-specific DNA methylation. Our work sheds light on the recent breeding history of potato, the functional organization of its tetraploid genome and has the potential to strengthen the future of genomics-assisted breeding.
Inhaled Ciclesonide for Patients With Asthma or Chronic Obstructive Pulmonary Disease and COVID-19—Reply
Authors: Brian M. Clemency, David J. Koster, Michael S. Blaiss
Journal: JAMA Internal Medicine (2022)

Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19
CHARACTERISTICS, PREDICTORS AND OUTCOMES OF EARLY MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR USE AFTER HEART TRANSPLANTATION; INSIGHTS FROM THE UNITED NETWORK FOR ORGAN SHARING (UNOS) DATABASE
Authors: Polydoros Kampaktsis, Ilias Doulamis, Elpiniki Makri, Ilias Kalamaras, Christoforos Papastergiopoulos, Maria Emfietzoglou, Paulino Alvarez, Anastasios Drosou, Alexandros Briasoulis
Journal: Journal of the American College of Cardiology (2022)
Clinical Images: Intraosseous calcification migration: journey to the center of the bone
Authors: Clément Cholet, Justine Mugnier, Anne Miquel, Juliette Petit, Jérémie Sellam, Lionel Arrivé
Journal: Arthritis & Rheumatology (2022)

Disclosure Form: Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality
Authors: P.J. Devereaux, Andre Lamy, Matthew T.V. Chan, René V. Allard, Vladimir V. Lomivorotov, Giovanni Landoni, Hong Zheng, Domenico Paparella, Michael H. McGillion, Emilie P. Belley-Côté, Joel L. Parlow, Malcolm J. Underwood, Chew Yin Wang, Nazari Dvirnik, Marat Abubakirov, Evgeny Fominskiy, Stephen Choi, Stephen Fremes, Fabrizio Monaco, Gerard Urrútia, Marialuz Maestre, Ludhmila A. Hajjar, Graham S. Hillis, Nicholas L. Mills, Vito Margari, Joseph D. Mills, J. Stephen Billing, Emily Methangkool, Carisi A. Polanczyk, Roberto Sant’Anna, Dmitry Shukevich, David Conen, Peter A. Kavsak, Matthew J. McQueen, Katheryn Brady, Jessica Spence, Yannick Le Manach, Rajibul Mian, Shun Fu Lee, Shrikant I. Bangdiwala, Sara Hussain, Flavia K. Borges, Shirley Pettit, Jessica Vincent, Gordon H. Guyatt, Salim Yusuf, Joseph S. Alpert, Harvey D. White, Richard P. Whitlock
Journal: New England Journal of Medicine (2022)

Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergoing cardiac surgery range widely (from >10 times to ≥70 times the upper reference limit for the assay). Limited evidence is available to support these recommendations.
Treatment of Oral Erosive Lichen Planus With Upadacitinib
Authors: Riccardo Balestri, Roberto Bortolotti, Giulia Rech, Carlo René Girardelli, Maria Grazia Zorzi, Michela Magnano
Journal: JAMA Dermatology (2022)

This case report describes a 45-year-old woman who presented with painful oral erosions and chronic human leukocyte antigen B27–positive psoriatic peripheral arthritis with associated recurrent anterior uveitis.
RACIAL/ETHNIC DIFFERENCES IN RISK FACTORS AND OUTCOMES IN YOUNG ADULTS PRESENTING WITH ACUTE MYOCARDIAL INFARCTION
Authors: Bryant A. Hammershaimb, Sarah Chiu, Karo Gyurjian, Jesse Goitia, Malini Nadadur, Yuh-Jer Shen, Ming-Sum Lee
Journal: Journal of the American College of Cardiology (2022)
Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales
Authors: Michele Bartoletti, Alberto Antonelli, Linda Bussini, Silvia Corcione, Daniele Roberto Giacobbe, Lorenzo Marconi, Renato Pascale, Silvia Dettori, Nour Shbaklo, Simone Ambretti, Paolo Gaibani, Tommaso Giani, Marco Coppi, Matteo Bassetti, Francesco Giuseppe De Rosa, Anna Marchese, Rossana Cavallo, Russell Lewis, Gian Maria Rossolini, Pierluigi Viale, Maddalena Giannella
Journal: Clinical Microbiology and Infection (2022)
Identifying Parkinson Risk Markers in Primary Care—Old Associations and New Insights
Authors: Bhavana Patel, Shannon Chiu, Melissa J. Armstrong
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Challenging the Myths of the Against Medical Advice Discharge
Authors: Matthew W. Wright
Journal: Annals of Internal Medicine (2022)

LettersMarch 2022Challenging the Myths of the Against Medical Advice DischargeMatthew W. Wright, MDMatthew W. Wright, MDSonoran Hospital Medicine, Scottsdale, ArizonaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Much of Alfandre's commentary (1) is correct (particularly regarding the obligation to provide medically necessary discharge prescriptions and appropriate follow-up appointments). However, I always treat legal advice given by a physician and not an attorney as questionable. Therefore, I would like to see an article on the legal aspects of an against medical advice (AMA) discharge written by an experienced attorney specializing in medical malpractice defense, not a physician.Reference1. Alfandre D. Annals for Hospitalists Inpatient Notes—Challenging the myths of the against medical advice discharge. Ann Intern Med. 2021;174:HO2-3. [PMID: 34662167] doi:10.7326/M21-3450 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Sonoran Hospital Medicine, Scottsdale, ArizonaDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L22-0014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAnnals for Hospitalists Inpatient Notes - Challenging the Myths of the Against Medical Advice Discharge David Alfandre Challenging the Myths of the Against Medical Advice Discharge Ronald Hirsch Challenging the Myths of the Against Medical Advice Discharge Karen E. Clark Challenging the Myths of the Against Medical Advice Discharge David Alfandre Metrics March 2022Volume 175, Issue 3Page: W23KeywordsBioethicsHospitalistsHospitalizationsInpatientsPatients ePublished: 15 March 2022 Issue Published: March 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
DNA replication fork speed underlies cell fate changes and promotes reprogramming
Authors: Tsunetoshi Nakatani, Jiangwei Lin, Fei Ji, Andreas Ettinger, Julien Pontabry, Mikiko Tokoro, Luis Altamirano-Pacheco, Jonathan Fiorentino, Elmir Mahammadov, Yu Hatano, Capucine Van Rechem, Damayanti Chakraborty, Elias R. Ruiz-Morales, Paola Y. Arguello Pascualli, Antonio Scialdone, Kazuo Yamagata, Johnathan R. Whetstine, Ruslan I. Sadreyev, Maria-Elena Torres-Padilla
Journal: Nature Genetics (2022)

Abstract Totipotency emerges in early embryogenesis, but its molecular underpinnings remain poorly characterized. In the present study, we employed DNA fiber analysis to investigate how pluripotent stem cells are reprogrammed into totipotent-like 2-cell-like cells (2CLCs). We show that totipotent cells of the early mouse embryo have slow DNA replication fork speed and that 2CLCs recapitulate this feature, suggesting that fork speed underlies the transition to a totipotent-like state. 2CLCs emerge concomitant with DNA replication and display changes in replication timing (RT), particularly during the early S-phase. RT changes occur prior to 2CLC emergence, suggesting that RT may predispose to gene expression changes and consequent reprogramming of cell fate. Slowing down replication fork speed experimentally induces 2CLCs. In vivo, slowing fork speed improves the reprogramming efficiency of somatic cell nuclear transfer. Our data suggest that fork speed regulates cellular plasticity and that remodeling of replication features leads to changes in cell fate and reprogramming.
BODY MASS INDEX AS A PREDICTOR OF MORTALITY IN PATIENTS ADMITTED WITH COVID-19, A RETROSPECTIVE STUDY
Authors: Mujahed Abualfoul, Yi Zhao, Victor Canela, Lawrence M. Hoang, Sri Naga Pavani Prathivada, Michael Vu, Lucas Wang, Priyanka Acharya, Manavjot Singh Sidhu
Journal: Journal of the American College of Cardiology (2022)
Abstract P4-04-02: A clinical-stage toll-like receptor 5 agonist, entolimod, boosts chemo-immunotherapy in pre-clinical TNBC by generating durable antitumor immunity
Authors: Craig M Brackett, Alyssa R Aldrich, Kellee F Greene, Bojidar Kandar, Jean Veith, Lyudmila G Burdelya, Scott I. Abrams, Andrei V Gudkov
Journal: Cancer Research (2022)

Abstract Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancer diagnoses, is the most aggressive form of the disease, and has the poorest clinical outcomes. Effective or durable therapies are lacking because these tumors lack targets for therapeutic intervention and rapidly develop resistance to chemotherapy (CTx). The FDA has now approved chemo-immunotherapy (CTx-I) regimens (αPD-L1/nab-Paclitaxel, αPD-1/CTx) as standard-of-care for early-stage, locally advanced, and metastatic TNBC. Despite these advancements, overall response rates remain relatively low and survival outcomes are extended for only a few months especially in the case of locally advanced or metastatic disease. Thus, the need exists to develop additional or alternative strategies to potentially build upon and improve CTx-I protocols for TNBC. To this end, our laboratory has explored the importance of engaging the innate immune response to augment the efficacy of CTx-I. Previously, we demonstrated that toll-like receptor (TLR) 5 signaling can elicit antitumor immunity against a preclinical model of metastatic TNBC. In particular, systemic administration of the TLR5 agonist, entolimod, stimulated durable CD8+ T cell immunity against 4T1, the prototypical preclinical PD-L1+ metastatic TNBC model. Here, using primary 4T1 tumors to mirror the clinical setting of locally advanced disease, we show that entolimod boosts the efficacy of CTx-I (αPD-L1/Paclitaxel) by causing tumor regression. Moreover, these mice completely reject a subsequent tumor challenge, highlighting that the entolimod/αPD-L1/Paclitaxel combination generates durable antitumor immunity in such advanced preclinical settings. Importantly, systemically administered entolimod was shown to be safe in Phase I clinical trials cumulatively involving nearly 200 subjects in both healthy volunteers and advanced cancer patients. Thus, this work will aid in formulating a more effective CTx-I treatment regimen with potentially important clinical implications for patients with locally advanced or metastatic TNBC. Citation Format: Craig M Brackett, Alyssa R Aldrich, Kellee F Greene, Bojidar Kandar, Jean Veith, Lyudmila G Burdelya, Scott I. Abrams, Andrei V Gudkov. A clinical-stage toll-like receptor 5 agonist, entolimod, boosts chemo-immunotherapy in pre-clinical TNBC by generating durable antitumor immunity [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-04-02.